Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 7

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 7
---
 offering price and underwriting discount in respect of such Pre-Funded Unit corresponds to 
 (i) a public offering price per Pre-Funded Warrant of $       ($                                      
 net of the underwriting discount), and (ii) a public offering price per Series L Warrant of $     .   |

| (3) | We have agreed to pay certain expenses of the underwriters in this offering and issue the underwriters                                         
 warrants to purchase a number of Depositary Shares equal to      % of the total Units being sold in this offering, at an exercise price equal  
 to 100% of the public offering price of each Unit in this offering, subject to certain anti-dilution adjustments, or the Underwriter Warrants. 
 The Underwriter Warrants will be non-exercisable for six (6) months from the date of effectiveness of the registration statement of which      
 this prospectus forms a part and will expire      years after such date (but no longer than five years from the commencement of sales of this  
 offering). The Underwriter Warrants and the Depositary Shares issuable upon exercise of the Underwriter Warrants are also being registered     
 under the registration statement of which this prospectus forms a part. We refer you to “Underwriting” on page [•]                             
 for additional information regarding underwritten compensation.                                                                                |

The offering is being underwritten
on a firm commitment basis. We have granted the underwriter an option exercisable within 45 days of the date of this prospectus to purchase from us up to additional Depositary Shares at a price of $ per share or up to Pre-Funded Warrants at a purchase price of $ per Pre-Funded Warrant and/or up to Series L Warrants at a purchase price of $ per Series L Warrant, less the underwriting discounts and commissions to cover over-allotments, if any. No underwriting discounts or commissions will be paid on any Series L Warrants purchased pursuant to the underwriter’s over-allotment option.

The underwriters expect to
deliver the securities to investors on or about , 2025.

<div align='center'>Sole Book Running Manager

The date of this prospectus is
, 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                         | Page |
| ABOUT THIS PROSPECTUS                                   |    1 |
| PRESENTATION OF FINANCIAL AND OTHER INFORMATION         |    2 |
| PROSPECTUS SUMMARY                                      |    4 |